39 research outputs found
The regional and global significance of nitrogen removal in lakes and reservoirs
Author Posting. © The Author(s), 2008. This is the author's version of the work. It is posted here by permission of Springer for personal use, not for redistribution. The definitive version was published in Biogeochemistry 93 (2009): 143-157, doi:10.1007/s10533-008-9272-x.Human activities have greatly increased the transport of biologically available N through
watersheds to potentially sensitive coastal ecosystems. Lentic water bodies (lakes and
reservoirs) have the potential to act as important sinks for this reactive N as it is
transported across the landscape because they offer ideal conditions for N burial in
sediments or permanent loss via denitrification. However, the patterns and controls on
lentic N removal have not been explored in great detail at large regional to global scales.
In this paper we describe, evaluate, and apply a new, spatially explicit, annual-scale,
global model of lentic N removal called NiRReLa (Nitrogen Retention in Reservoirs and
Lakes). The NiRReLa model incorporates small lakes and reservoirs than have been
included in previous global analyses, and also allows for separate treatment and analysis
of reservoirs and natural lakes. Model runs for the mid-1990s indicate that lentic systems
are indeed important sinks for N and are conservatively estimated to remove 19.7 Tg N
yr-1 from watersheds globally. Small lakes (< 50 km2) were critical in the analysis,
retaining almost half (9.3 Tg N yr-1) of the global total. In model runs, capacity of lakes
and reservoirs to remove watershed N varied substantially (0-100%) both as a function of
climate and the density of lentic systems. Although reservoirs occupy just 6% of the
global lentic surface area, we estimate they retain approximately 33% of the total N
removed by lentic systems, due to a combination of higher drainage ratios (catchment
surface area : lake or reservoir surface area), higher apparent settling velocities for N, and
greater N loading rates in reservoirs than in lakes. Finally, a sensitivity analysis of
NiRReLa suggests that, on-average, N removal within lentic systems will respond more
strongly to changes in land use and N loading than to changes in climate at the global
scale.The NSF26 Research Coordination Network on denitrification for support for collaboration
(award number DEB0443439 to S.P. Seitzinger and E.A. Davidson). This project was
also supported by grants to J.A. Harrison from California Sea Grant (award number
RSF8) and from the U.S. Geological Survey 104b program and R. Maranger (FQRNT
Strategic Professor)
Beta-HPV E6 Contributes To Skin Cancer by Hindering DNA Repair
<div><p>Recent work has explored a putative role for the E6 protein from some ÎČ-human papillomavirus genus (ÎČ-HPVs) in the development of non-melanoma skin cancers, specifically ÎČ-HPV 5 and 8 E6. Because these viruses are not required for tumor maintenance, they are hypothesized to act as co-factors that enhance the mutagenic capacity of UV-exposure by disrupting the repair of the resulting DNA damage. Supporting this proposal, we have previously demonstrated that UV damage signaling is hindered by ÎČ-HPV 5 and 8 E6 resulting in an increase in both thymine dimers and UV-induced double strand breaks (DSBs). Here we show that ÎČ-HPV 5 and 8 E6 further disrupt the repair of these DSBs and provide a mechanism for this attenuation. By binding and destabilizing a histone acetyltransferase, p300, ÎČ-HPV 5 and 8 E6 reduce the enrichment of the transcription factor at the promoter of two genes critical to the homology dependent repair of DSBs (BRCA1 and BRCA2). The resulting diminished BRCA1/2 transcription not only leads to lower protein levels but also curtails the ability of these proteins to form repair foci at DSBs. Using a GFP-based reporter, we confirm that this reduced foci formation leads to significantly diminished homology dependent repair of DSBs. By deleting the p300 binding domain of ÎČ-HPV 8 E6, we demonstrate that the loss of robust repair is dependent on viral-mediated degradation of p300 and confirm this observation using a combination of p300 mutants that are ÎČ-HPV 8 E6 destabilization resistant and p300 knock-out cells. In conclusion, this work establishes an expanded ability of ÎČ-HPV 5 and 8 E6 to attenuate UV damage repair, thus adding further support to the hypothesis that ÎČ-HPV infections play a role in skin cancer development by increasing the oncogenic potential of UV exposure.</p></div
Response time variability and response inhibition predict affective problems in adolescent girls, not in boys: the TRAILS study
The present study examines the relationship between neurocognitive functioning and affective problems through adolescence, in a cross-sectional and longitudinal perspective. Baseline response speed, response speed variability, response inhibition, attentional flexibility and working memory were assessed in a cohort of 2,179 adolescents (age 10â12Â years) from the TRacking Adolescentsâ Individual Lives Survey (TRAILS). Affective problems were measured with the DSM-oriented Affective Problems scale of the Youth Self Report at wave 1 (baseline assessment), wave 2 (after 2.5Â years) and wave 3 (after 5Â years). Cross-sectionally, baseline response speed, response time variability, response inhibition and working memory were associated with baseline affective problems in girls, but not in boys. Longitudinally, enhanced response time variability predicted affective problems after 2.5 and 5Â years in girls, but not in boys. Decreased response inhibition predicted affective problems after 5Â years follow-up in girls, and again not in boys. The results are discussed in light of recent insights in gender differences in adolescence and stateâtrait issues in depression
Meta-analysis of genome-wide association studies for cattle stature identifies common genes that regulate body size in mammals
peer-reviewedH.D.D., A.J.C., P.J.B. and B.J.H. would like to acknowledge the Dairy Futures
Cooperative Research Centre for funding. H.P. and R.F. acknowledge funding
from the German Federal Ministry of Education and Research (BMBF) within the
AgroClustEr âSynbreedâSynergistic Plant and Animal Breedingâ (grant 0315527B).
H.P., R.F., R.E. and K.-U.G. acknowledge the Arbeitsgemeinschaft SĂŒddeutscher
RinderzĂŒchter, the Arbeitsgemeinschaft Ăsterreichischer FleckviehzĂŒchter
and ZuchtData EDV Dienstleistungen for providing genotype data. A. Bagnato
acknowledges the European Union (EU) Collaborative Project LowInputBreeds
(grant agreement 222623) for providing Brown Swiss genotypes. Braunvieh Schweiz
is acknowledged for providing Brown Swiss phenotypes. H.P. and R.F. acknowledge
the German Holstein Association (DHV) and the ConfederaciĂłn de Asociaciones
de Frisona Española (CONCAFE) for sharing genotype data. H.P. was financially
supported by a postdoctoral fellowship from the Deutsche Forschungsgemeinschaft
(DFG) (grant PA 2789/1-1). D.B. and D.C.P. acknowledge funding from the
Research Stimulus Fund (11/S/112) and Science Foundation Ireland (14/IA/2576).
M.S. and F.S.S. acknowledge the Canadian Dairy Network (CDN) for providing the
Holstein genotypes. P.S. acknowledges funding from the Genome Canada project
entitled âWhole Genome Selection through Genome Wide Imputation in Beef Cattleâ and acknowledges WestGrid and Compute/Calcul Canada for providing
computing resources. J.F.T. was supported by the National Institute of Food and
Agriculture, US Department of Agriculture, under awards 2013-68004-20364 and
2015-67015-23183. A. Bagnato, F.P., M.D. and J.W. acknowledge EU Collaborative
Project Quantomics (grant 516 agreement 222664) for providing Brown Swiss
and Finnish Ayrshire sequences and genotypes. A.C.B. and R.F.V. acknowledge
funding from the publicâprivate partnership âBreed4Foodâ (code BO-22.04-011-
001-ASG-LR) and EU FP7 IRSES SEQSEL (grant 317697). A.C.B. and R.F.V.
acknowledge CRV (Arnhem, the Netherlands) for providing data on Dutch and
New Zealand Holstein and Jersey bulls.Stature is affected by many polymorphisms of small effect in humans1. In contrast, variation in dogs, even within breeds, has been suggested to be largely due to variants in a small number of genes2,3. Here we use data from cattle to compare the genetic architecture of stature to those in humans and dogs. We conducted a meta-analysis for stature using 58,265 cattle from 17 populations with 25.4 million imputed whole-genome sequence variants. Results showed that the genetic architecture of stature in cattle is similar to that in humans, as the lead variants in 163 significantly associated genomic regions (P < 5 Ă 10â8) explained at most 13.8% of the phenotypic variance. Most of these variants were noncoding, including variants that were also expression quantitative trait loci (eQTLs) and in ChIPâseq peaks. There was significant overlap in loci for stature with humans and dogs, suggesting that a set of common genes regulates body size in mammals
The James Webb Space Telescope Mission
Twenty-six years ago a small committee report, building on earlier studies,
expounded a compelling and poetic vision for the future of astronomy, calling
for an infrared-optimized space telescope with an aperture of at least .
With the support of their governments in the US, Europe, and Canada, 20,000
people realized that vision as the James Webb Space Telescope. A
generation of astronomers will celebrate their accomplishments for the life of
the mission, potentially as long as 20 years, and beyond. This report and the
scientific discoveries that follow are extended thank-you notes to the 20,000
team members. The telescope is working perfectly, with much better image
quality than expected. In this and accompanying papers, we give a brief
history, describe the observatory, outline its objectives and current observing
program, and discuss the inventions and people who made it possible. We cite
detailed reports on the design and the measured performance on orbit.Comment: Accepted by PASP for the special issue on The James Webb Space
Telescope Overview, 29 pages, 4 figure
Recommended from our members
Effect of Hydrocortisone on Mortality and Organ Support in Patients With Severe COVID-19: The REMAP-CAP COVID-19 Corticosteroid Domain Randomized Clinical Trial.
Importance: Evidence regarding corticosteroid use for severe coronavirus disease 2019 (COVID-19) is limited. Objective: To determine whether hydrocortisone improves outcome for patients with severe COVID-19. Design, Setting, and Participants: An ongoing adaptive platform trial testing multiple interventions within multiple therapeutic domains, for example, antiviral agents, corticosteroids, or immunoglobulin. Between March 9 and June 17, 2020, 614 adult patients with suspected or confirmed COVID-19 were enrolled and randomized within at least 1 domain following admission to an intensive care unit (ICU) for respiratory or cardiovascular organ support at 121 sites in 8 countries. Of these, 403 were randomized to open-label interventions within the corticosteroid domain. The domain was halted after results from another trial were released. Follow-up ended August 12, 2020. Interventions: The corticosteroid domain randomized participants to a fixed 7-day course of intravenous hydrocortisone (50 mg or 100 mg every 6 hours) (nâ=â143), a shock-dependent course (50 mg every 6 hours when shock was clinically evident) (nâ=â152), or no hydrocortisone (nâ=â108). Main Outcomes and Measures: The primary end point was organ support-free days (days alive and free of ICU-based respiratory or cardiovascular support) within 21 days, where patients who died were assigned -1 day. The primary analysis was a bayesian cumulative logistic model that included all patients enrolled with severe COVID-19, adjusting for age, sex, site, region, time, assignment to interventions within other domains, and domain and intervention eligibility. Superiority was defined as the posterior probability of an odds ratio greater than 1 (threshold for trial conclusion of superiority >99%). Results: After excluding 19 participants who withdrew consent, there were 384 patients (mean age, 60 years; 29% female) randomized to the fixed-dose (nâ=â137), shock-dependent (nâ=â146), and no (nâ=â101) hydrocortisone groups; 379 (99%) completed the study and were included in the analysis. The mean age for the 3 groups ranged between 59.5 and 60.4 years; most patients were male (range, 70.6%-71.5%); mean body mass index ranged between 29.7 and 30.9; and patients receiving mechanical ventilation ranged between 50.0% and 63.5%. For the fixed-dose, shock-dependent, and no hydrocortisone groups, respectively, the median organ support-free days were 0 (IQR, -1 to 15), 0 (IQR, -1 to 13), and 0 (-1 to 11) days (composed of 30%, 26%, and 33% mortality rates and 11.5, 9.5, and 6 median organ support-free days among survivors). The median adjusted odds ratio and bayesian probability of superiority were 1.43 (95% credible interval, 0.91-2.27) and 93% for fixed-dose hydrocortisone, respectively, and were 1.22 (95% credible interval, 0.76-1.94) and 80% for shock-dependent hydrocortisone compared with no hydrocortisone. Serious adverse events were reported in 4 (3%), 5 (3%), and 1 (1%) patients in the fixed-dose, shock-dependent, and no hydrocortisone groups, respectively. Conclusions and Relevance: Among patients with severe COVID-19, treatment with a 7-day fixed-dose course of hydrocortisone or shock-dependent dosing of hydrocortisone, compared with no hydrocortisone, resulted in 93% and 80% probabilities of superiority with regard to the odds of improvement in organ support-free days within 21 days. However, the trial was stopped early and no treatment strategy met prespecified criteria for statistical superiority, precluding definitive conclusions. Trial Registration: ClinicalTrials.gov Identifier: NCT02735707
Numerical simulations examining the possible role of anthropogenic and volcanic emissions during the 1997 Indonesian fires
Exome sequencing identifies rare damaging variants in ATP8B4 and ABCA1 as risk factors for Alzheimerâs disease
Alzheimerâs disease (AD), the leading cause of dementia, has an estimated heritability of approximately 70%1. The genetic component of AD has been mainly assessed using genome-wide association studies, which do not capture the risk contributed by rare variants2. Here, we compared the gene-based burden of rare damaging variants in exome sequencing data from 32,558 individualsâ16,036 AD cases and 16,522 controls. Next to variants in TREM2, SORL1 and ABCA7, we observed a significant association of rare, predicted damaging variants in ATP8B4 and ABCA1 with AD risk, and a suggestive signal in ADAM10. Additionally, the rare-variant burden in RIN3, CLU, ZCWPW1 and ACE highlighted these genes as potential drivers of respective AD-genome-wide association study loci. Variants associated with the strongest effect on AD risk, in particular loss-of-function variants, are enriched in early-onset AD cases. Our results provide additional evidence for a major role for amyloid-ÎČ precursor protein processing, amyloid-ÎČ aggregation, lipid metabolism and microglial function in AD
Biomarker A+T-: is this Alzheimer's disease or not? A combined CSF and pathology study
The biological definition of Alzheimer's disease using CSF biomarkers requires both abnormal amyloid (A) and p-tau (T) levels. However, biomarkers and corresponding cutoffs may not always reflect the presence or absence of pathology. Previous studies suggest that up to 32% of autopsy-confirmed Alzheimer's disease individuals show normal CSF p-tau levels in vivo, but these studies are sparse and had small sample sizes. Therefore, we studied in three independent autopsy cohorts whether CSF A+T- excluded Alzheimer's disease based on autopsy or not. We included 215 individuals with ante-mortem CSF collection and autopsy performed from three cohorts: the Amsterdam Dementia Cohort (n = 80, 37 (46%) Alzheimer's disease at autopsy, time between CSF collection and death 4.5±2.9 years); from the Antwerp Dementia Cohort (n = 92, 84 (91%) Alzheimer's disease at autopsy, time CSF collection to death 1.7±2.3 years); and from the Alzheimer's Disease Neuroimaging Initiative (n = 43, 31 (72%) Alzheimer's disease at autopsy, time CSF collection to death 5.1±2.5 years). Biomarker profiles were based on dichotomized CSF AÎČ1-42 and p-tau levels. Accuracy of CSF AT profiles to detect autopsy-confirmed Alzheimer's disease was assessed. Lastly, we investigated whether the concordance of AT profiles with autopsy diagnosis improved when CSF was collected closer to death in 9 (10%) Antwerp Dementia Cohort and 30 (70%) Alzheimer's Disease Neuroimaging Initiative individuals with repeated CSF measurements available. In total, 50-73% of A+T- individuals and 100% of A+T+ individuals had Alzheimer's disease at autopsy. Amyloid status showed the highest accuracy to detect autopsy-confirmed Alzheimer's disease (accuracy, sensitivity and specificity in Amsterdam Dementia Cohort: 88%, 92% and 84%; in Antwerp Dementia Cohort: 87%, 94% and 12%; and in Alzheimer's Disease Neuroimaging Initiative: 86%, 90% and 75% respectively). The addition of CSF p-tau did not further improve these estimates. We observed no differences in demographics or on degree of Alzheimer's disease neuropathology between A+T- and A+T+ individuals with autopsy-confirmed Alzheimer's disease. All individuals with repeated CSF measurements remained stable in AÎČ1-42 status during follow-up. None of the Alzheimer's disease individuals with a normal p-tau status changed to abnormal, however four (44%) Antwerp Dementia Cohort individuals and two (7%) Alzheimer's Disease Neuroimaging Initiative individuals changed from abnormal to normal p-tau status over time, and all had Alzheimer's disease at autopsy. In summary, we found that up to 73% of A+T- individuals did have Alzheimer's disease at autopsy. This should be taken into account in both research and clinical settings
Screening for paroxysmal atrial fibrillation in primary care using Holter monitoring and intermittent, ambulatory single-lead electrocardiography
BACKGROUND: Timely detection of atrial fibrillation (AF) is important because of its increased risk of thrombo-embolic events. Single time point screening interventions fall short in detection of paroxysmal AF, which requires prolonged electrocardiographic monitoring, usually using a Holter. However, traditional 24-48âŻh Holter monitoring is less appropriate for screening purposes because of its low diagnostic yield. Intermittent, ambulatory screening using a single-lead electrocardiogram (1âŻL-ECG) device can offer a more efficient alternative. METHODS: Primary care patients of â„65âŻyears participated in an opportunistic screening study for AF. We invited patients with a negative 12âŻL-ECG to wear a Holter monitor for two weeks and to use a MyDiagnostick 1âŻL-ECG device thrice daily. We report the yield of paroxysmal AF found by Holter monitoring and calculate the diagnostic accuracy of the 1âŻL-ECG device's built-in AF detection algorithm with the Holter monitor as reference standard. RESULTS: We included 270 patients, of whom four had AF in a median of 8.0âŻdays of Holter monitoring, a diagnostic yield of 1.5% (95%-CI: 0.4-3.8%). In 205 patients we performed simultaneous 1âŻL-ECG screening. For diagnosing AF based on the 1âŻL-ECG device's AF detection algorithm, sensitivity was 66.7% (95%-CI: 9.4-99.2%), specificity 68.8% (95%-CI: 61.9-75.1%), positive predictive value 3.1% (95%-CI: 1.4-6.8%) and negative predictive value 99.3% (95%-CI: 96.6-99.9%). CONCLUSION: We found a low diagnostic yield of paroxysmal AF using Holter monitoring in elderly primary care patients with a negative 12âŻL-ECG. The diagnostic accuracy of an intermittently, ambulatory used MyDiagnostick 1âŻL-ECG device as interpreted by its built-in AF detection algorithm is limited